Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | RECQL | P46063 | 8/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5070920 | 0.98 | PLA2G1B (0.67) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| Hydrochloric Acid SCHEMBL28352199 | 0.98 | PLA2G1B (0.67) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL17244102 | 0.84 | PLA2G1B (0.65) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL20417370 | 0.83 | PLA2G1B (0.64) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL10893521 | 0.83 | PLA2G1B (0.48) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL11950426 | 0.83 | PLA2G1B (0.64) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL11274987 | 0.82 | PLA2G1B (0.47) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL10804215 | 0.82 | PLA2G1B (0.47) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL633687 | 0.81 | ALOX15 (0.70) | PLA2G1BALOX15KDM4ERECQLTDP1 | |
| SCHEMBL13660697 | 0.81 | ALOX15 (0.70) | PLA2G1BALOX15KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2884962-B1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INT LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20150216799-A1 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC | 2015-08-06 | — | — | US | claimed |
| EP-2884962-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | Smartek International LLC (US) | 2015-06-24 | — | — | EP | claimed |
| WO-2014028796-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC (US) | 2014-02-20 | — | — | WO | claimed |
| US-20070191368-A1 | Inhibition of tissue damage to skin from radiation treatment therapy | BISSETT DONALD L | 2007-08-16 | — | — | US | claimed |
| US-20250213545-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASES, COMPRISING FEXOFENADINE | STANDIGM INC. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2024035015-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASES, COMPRISING FEXOFENADINE | 아주대학교산학협력단 | 2024-02-15 | — | — | WO | disclosed |
| US-11701360-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | Genuv Inc. (KR) | 2023-07-18 | — | — | US | disclosed |
| EP-4180517-A1 | PRE-CONDITIONED MESENCHYMAL STEM CELLS AND PREPARATIONS AND APPLICATIONS THEREOF | Buddhist Tzu Chi Medical Foundation (TW) | 2023-05-17 | — | — | EP | disclosed |
| CN-116103231-A | Preconditioning mesenchymal stem cells, preparation and application thereof | 佛教慈济医疗财团法人 | 2023-05-12 | — | — | CN | disclosed |
| US-20230145213-A1 | Pre-conditioned mesenchymal stem cells and preparations and applications thereof | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2023-05-11 | — | — | US | disclosed |
| EP-1835287-A2 | Method and test kits for determining neuroendocrinal diseases | Bieger, Wilfried P. (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-02-02 | — | — | US | disclosed |
| US-5081033-A | Effective amount of ammonium ions to enhance chlamydospore por duction by strains of Candida albicans | WADLEY TECHNOLOGIES, INC. (US) | 1992-01-14 | — | — | US | disclosed |
| US-4847128-A | INCUBATION, ANALYZING | WADLEY TECHNOLOGIES, INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0160743-B1 | MINIATURIZED YEAST IDENTIFICATION SYSTEM | Wadley Technologies, Inc. (US) | 1989-03-22 | — | — | EP | disclosed |
| US-4728607-A | CULTURE CONTAINER FOR VIEWING UNDER MICROSCOPE | J. K. AND SUSIE L. WADLEY RESEARCH INSTITUTE AND BLOOD BANK (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0160743-A2 | Miniaturized yeast identification system | Wadley Technologies, Inc. (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4144133-A | OXGALL, SAPONIN, SUBSTRATE FOR PHENOL OXIDASE | J. K. AND SUSIE L. WADLEY RESEARCH INSTITUTE AND BLOOD BANK (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701360-B2 | Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition | NOTCH2, NOTCH1, APP | PLA2G1B 588/4885ALOX15 775/4885KDM4E 2853/4885 |
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | SNCA, DBH, PARK7 | PLA2G1B 1480/4885ALOX15 1467/4885KDM4E 3395/4885 |
| US-12303564-B2 | Composite chitosan-tannin-active agent compositions and methods of making and using same | TTPA, CHIA, CHIT1 | PLA2G1B 694/4885ALOX15 737/4885KDM4E 2781/4885 |
| US-20230145213-A1 | Pre-conditioned mesenchymal stem cells and preparations and applications thereof | NEFM, EXOSC10, EXOSC5 | PLA2G1B 376/4885ALOX15 233/4885KDM4E 3956/4885 |
| US-20250213545-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF NEURODEGENERATIVE DISEASES, COMPRISING FEXOFENADINE | SNCA, PARK7, CAT | PLA2G1B 3042/4885ALOX15 411/4885KDM4E 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.